主持国家重点研发计划研究课题2项：

①新型溶瘤病毒肿瘤治疗的临床试验及治疗机制研究，(项目批准号：2019YFC1316104)，执行年限：2019.12-2021.12年，已结题，资助金额：1097万元。

②肿瘤细胞体外药敏技术体系的临床评估及验证（项目批准号：2022YFC2403401），执行年限：2022.11-2025.10，目前在研，资助金额：280 万元。

主持国家自然科学基金项目3项：

①PH敏感性脂质体杂合红细胞膜包被的溶瘤病毒静脉递送技术研发及在结直肠癌中的作用和机制研究(项目批准号：82073368)，执行年限：2021.01-2024.12，目前在研，资助金额：55万元；

②FN13’UTR作为一个新的ceRNA在胃癌中的作用和机制研究(项目批准号：81871960)，执行年限：2019.01-2022.12年,已结题，资助金额：57万元；

③国家青年自然科学基金项目1项：基于PAK1自我抑制域的胃癌小分子靶向药物筛选模型的建立及药物筛选(项目批准号：81001092)，执行年限：2011-2013年，已结题，资助金额：21万元。

辽宁省“兴辽英才计划” 青年拔尖人才，“脂质体包被溶瘤病毒串联自驱动工程菌组合生物体制剂的抗肿瘤疗效及其机制的研究” (项目批准号：XLYC2007071)，资助强度50万元，2021.1-2023.12

1. Ban W,Sun M, Huang H, Huang W, Pan S, Liu P, Li B, Cheng Z, He Z, Liu F, Sun J. Engineered bacterial outer membrane vesiclesencapsulating oncolytic adenoviruses enhance the efficacy of cancer virotherapyby augmenting tumor cell autophagy. NatCommun. 2023 May 22;14(1):2933.通讯作者 IF=17.694

2. Wu Q, Huang H, Sun M, Zhang R, Wang J, ZhengH, Zhu C, Yang S, Shen X, Shi J, Liu F, Wu W, Sun J, Liu F, Li H, Gu Z.Inhibition of Tumor Metastasis by Liquid Nitrogen-Shocked Tumor Cells withOncolytic Viruses Infection. Adv Mater. 2023 Apr 1:e2212210.通讯作者 IF=32.086

3. HuangH, Liu M, Sun M, Duan S, Pan S, Liu P, Cheng Z, Ergonul O, Can F, Wang Z, PangZ, Liu F. Virus-Protein Corona Replacement Strategy to Improve the AntitumorEfficacy of Intravenously Injected Oncolytic Adenovirus. ACS Nano. 2023 Jun 27.通讯作者 IF=18.027

4. Yang S, Wang M, Wang T, Sun M, Huang H, Shi X, Duan S, WuY, Zhu J, Liu F. Self-assembled short peptides: Recent advances and strategiesfor potential pharmaceutical applications. Materials TodayBio. 2023 April 10:100644 通讯作者 IF= 10.761

5.Duan S, Wang S, Qiao L,Yu X, Wang N, Chen L, Zhang X, Zhao X, Liu H, Wang T, Wu Y, Li N, Liu F.Oncolytic Virus-Driven Biotherapies from Bench to Bedside. Small. 2023 Mar6:e2206948. 通讯作者 IF=15.153

6.Hanwei Huang, Mengchi Sun,Mingyang Liu, Siwei Pan, Pengfei Liu, Zhenguo Cheng, Jia Li, Huimian Xu, FunanLiu, Zhiqing Pang,Full encapsulation of oncolytic virus using hybriderythroctye-liposome membranes for augmented anti-refractory tumoreffectiveness,Nano Today,Volume 47,2022,101671,ISSN 1748-0132.通讯作者IF=18.962

7. Sun M, Yang S, Huang H, Gao P, Pan S, Cheng Z, He Z,Wang Z, Sun J, Liu F. Boarding Oncolytic Viruses onto Tumor-HomingBacterium-Vessels for Augmented Cancer Immunotherapy. Nano Lett. 2022 Jun22;22(12):5055-5064. 通讯作者IF:11.189

8. BanW, Guan J, Huang H, He Z, Sun M, Liu F, Sun J. Emerging systemic deliverystrategies of oncolytic viruses: A key step toward cancer immunotherapy. NanoRes. 2022;15(5):4137-4153.通讯作者IF:8.897

9.Pan S, Gao Q, Chen Q, Liu P, Tan Y, Liu F, Xu H. Integrativeanalysis-based identification and validation of a prognostic immune cellinfiltration-based model for patients with advanced gastric cancer. Int Immunopharmacol. 2021Dec;101(Pt B):108258. 通讯作者IF:4.932

10. Ouyang B,Liu F,Ruan S, Liu Y, Guo H, Cai Z, Yu X, PangZ, Shen S.Localized Free Radicals Burst Triggered by NIR-II Light forAugmented Low-Temperature Photothermal Therapy. ACS Appl Mater Interfaces.2019;11(42):38555-38567.第一作者IF: 8.456

11. Pan SW, Wang PL, Huang HW, Luo L,Wang X, Wang T, Liu FN, Xu HM. A Proposal of a Personalized Surveillance Strategy for Gastric. Gastroenterol Res Pract. 2019;2019:3248727.通讯作者IF:1.825

12. Duan S, Gong B, Wang P, Huang H, Luo L, Liu F. Novelprognostic biomarkers of gastric cancer based on gene expression microarray:COL12A1, GSTA3, FGA and FGG. Molecular medicine reports. 2018;18(4):3727-36.通讯作者IF: 1.922

13.Lai S, Chen JN, Huang HW, Zhang XY, Jiang HL, Li W, Wang PL, Wang J, Liu FN. Structure activityrelationships of chrysoeriol and analogs as dual cMet and VEGFR2 tyrosinekinase inhibitors. Oncology reports. 2018;40(3):1650-6.通讯作者IF: 2.976

14.Wang PL, Huang JY, Zhu Z, Gong BC, Huang HW, Duan SJ, Xu HM,Liu FN. Development of a risk-scoringsystem to evaluate the serosal invasion for macroscopic serosal invasionpositive gastric cancer patients. European journal of surgical oncology.2018;44(5):600-6.通讯作者IF: 3.688

15.Huang. H, Jiang. H, Zhang. X, Li. W, Wang. P, Liu. F, Wang. J, Bai. M, Cheng. M.Computer-aided drug design, synthesis and identification of disulfide compoundsas novel and potent allosteric PAK1 inhibitors. . RSCAdvances. 2018;8((50)):11894-901.通讯作者IF: 2.936

16.Xiao F, Cheng Z, Wang P, Gong B, Huang H, Xing Y, Liu F. MicroRNA-28-5p inhibits the migration andinvasion of gastric cancer cells by suppressing AKT phosphorylation. Oncology letters. 2018;15(6):9777-85.通讯作者IF: 1.664

17.Huang HW, Zhang XY, Song PL, Jiang HL, Li W, Wang PL, Wang J, Liu FN.Old drugnew tricks: Chlorhexidine acts as a potential allosteric inhibitor toward PAK1.Biochemical and biophysical research communications. 2018;495(1):728-32.通讯作者 IF: 2.559

18.Duan SJ, Gao ZM, Wang PL, Gong BC, Huang HW, Luo L, Wang X, Xing YN, Xu HM, Liu FN. Rareupper gastrointestinal hemorrhage of cetuximab: A case report. Medicine.2017;96(51):e9391.通讯作者IF: 2.208 

19.Wang PL, Xiao FT, Gong BC, Liu FN.Alcohol drinking and gastric cancer risk: a meta-analysisof observational studies. Oncotarget. 2017;8(58):99013-23.通讯作者IF: 5.168 

20. Liu F, Cheng Z, Li X, Li Y, Zhang H, Li J, Liu F, XuH, Li F. A Novel Pak1/ATF2/miR-132 Signaling Axis Is Involved in theHematogenous Metastasis of Gastric Cancer Cells. Molecular therapy Nucleic acids. 2017;8:370-82.第一作者IF: 5.66  

21.Cheng Z, Zhang D, Gong B, Wang P, Liu F.CD163 as a novel target gene of STAT3 is a potential therapeutic target forgastric cancer. Oncotarget. 2017;8(50):87244-62.通讯作者IF: 5.168

22.Wang PL, Xiao FT, Gong BC, Liu FN,Xu HM. A Nomogram for Predicting Overall Survival ofGastric Cancer Patients with Insufficient Lymph Nodes Examined. Journal ofgastrointestinal surgery. 2017;21(6):947-56.通讯作者IF: 2.813 

23. Gong B, Li Y, Cheng Z, Wang P, Luo L, Huang H, Duan S,Liu F. GRIK3: A novel oncogenic protein related to tumorTNM stage, lymph node metastasis, and poor prognosis of GC. Tumour biology: the journal of the International Society for Oncodevelopmental Biology andMedicine. 2017;39(6):1010428317704364.通讯作者IF:3.65 

24. Liu F,Li X, Wang C, Cai X,Du Z, Xu H, Li F. Downregulation of p21-activated kinase-1 inhibits thegrowth of gastric cancer cells involving cyclin B1. Int JCancer. 2009 Dec1;125(11):2511-9.第一作者IF:4.722

人才层次：省级；校级

人才入选项目：辽宁省兴辽英才青年拔尖人才；辽宁省“百千万人才工程”千人层次人选；中国医科大学青年拔尖人才

是否具有国际合作：是

是否具有国外访学经历：匹兹堡大学、范德堡大学访问学者

所在团队及任职情况：任职中国医科大学附属第一医院药物临床试验Ⅰ期中心主任

曾获辽宁省兴辽英才青年拔尖人才；

辽宁省“百千万人才工程”千人层次人选；

辽宁省向上向善好青年；

中国医科大学青年拔尖人才